Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
| ▸ | RAB9A | P51151 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.54 |
| ▸ | PKM | P14618 | 1/20 | 0.54 |
| ▸ | POLB | P06746 | 1/20 | 0.52 |
| ▸ | FKBP1A | P62942 | 1/20 | 0.50 |
| ▸ | ACE | P12821 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | DPP4 | P27487 | 1/20 | 0.47 |
| ▸ | PEPD | P12955 | 1/20 | 0.47 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6882664 | 1.00 | LMNA (0.54) | LMNARAB9ASMN1; SMN2PKMPOLB | |
| SCHEMBL5491755 | 1.00 | LMNA (0.54) | LMNARAB9ASMN1; SMN2PKMPOLB | |
| SCHEMBL16620921 | 0.93 | LMNA (0.49) | LMNARAB9ASMN1; SMN2PKMPOLB | |
| SCHEMBL31159664 | 0.93 | LMNA (0.49) | LMNARAB9ASMN1; SMN2PKMPOLB | |
| SCHEMBL31589872 | 0.93 | LMNA (0.49) | LMNARAB9ASMN1; SMN2PKMPOLB | |
| SCHEMBL4684947 | 0.93 | LMNA (0.49) | LMNARAB9ASMN1; SMN2PKMPOLB | |
| SCHEMBL18796576 | 0.93 | LMNA (0.49) | LMNARAB9ASMN1; SMN2PKMPOLB | |
| SCHEMBL4684952 | 0.93 | LMNA (0.49) | LMNARAB9ASMN1; SMN2PKMPOLB | |
| SCHEMBL5282326 | 0.91 | LMNA (0.48) | LMNARAB9ASMN1; SMN2PKMPOLB | |
| SCHEMBL31589511 | 0.91 | LMNA (0.48) | LMNARAB9ASMN1; SMN2PKMPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1743884-A1 | Progrugs to d-prolines | F.HOFFMANN-LA ROCHE AG (CH) | 2007-01-17 | — | — | EP | claimed |
| US-6903129-B2 | D-proline prodrugs | HOFFMAN-LA ROCHE INC. (US) | 2005-06-07 | — | — | US | claimed |
| US-20030134891-A1 | New D-proline prodrugs | PENTRAXIN THERAPEUTICS LTD. (GB) | 2003-07-17 | — | — | US | claimed |
| EP-1743884-A1 | Progrugs to d-prolines | F.HOFFMANN-LA ROCHE AG (CH) | 2007-01-17 | — | — | EP | disclosed |
| US-6903129-B2 | D-proline prodrugs | HOFFMAN-LA ROCHE INC. (US) | 2005-06-07 | — | — | US | disclosed |
| US-20030134891-A1 | New D-proline prodrugs | PENTRAXIN THERAPEUTICS LTD. (GB) | 2003-07-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030134891-A1 | New D-proline prodrugs | PCNP, PREP, APP | LMNA 794/4885RAB9A 3149/4885SMN1; SMN2 762/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.